Oragenics, Inc.
OGEN
$0.59
$0.035.45%
AMEX
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
5/7/2026
-
Globe Newswire
4/20/2026
-
Globe Newswire
Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury
4/13/2026
-
Globe Newswire
3/17/2026
-
Globe Newswire
3/12/2026
-
Globe Newswire
3/11/2026
-
Globe Newswire
3/10/2026
-
Globe Newswire
2/9/2026
-
Globe Newswire
2/3/2026
-
Globe Newswire
2/2/2026
-
Globe Newswire
1/14/2026
-
Globe Newswire
8/11/2025
-
Globe Newswire
7/31/2025
-
Globe Newswire
7/16/2025
-
Globe Newswire
7/2/2025
-
Globe Newswire
7/1/2025
-
Globe Newswire
6/10/2025
-
Globe Newswire
5/28/2025
-
Globe Newswire
5/13/2025
-
Globe Newswire
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
--
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Monday, March 16, 2026
Period Date
Wednesday, December 31, 2025
Next Filing
Week of May 4 and 8 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
813 286 7900
Address
9015 Town Center Parkway
Lakewood Ranch, FL 34202
Lakewood Ranch, FL 34202
Country
Year Founded
Business Description
Sector
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United...
more